Acadia Healthcare Company, Inc.

Acadia Healthcare Company, Inc. announced a preliminary settlement in consolidated stockholder derivative actions. The settlement, preliminarily approved by the U.S. District Court for the Middle District of Tennessee, includes a $12,000,000 cash payment from insurers to the Company and the implementation of corporate governance reforms. The derivative actions alleged misleading statements, issues with care and staffing, UK operations, and insider trading.

Acadia Healthcare reported second-quarter 2026 financial results, with revenue remaining approximately flat at $865.8 million. Net income attributable to Acadia significantly decreased by 64% to $10.9 million, and Adjusted EBITDA fell by 26% to $149.2 million, primarily due to a $28.6 million adjustment to professional and general liability reserves. The company expanded its operations by adding 240 licensed beds and two new Comprehensive Treatment Center locations, and updated its full-year 2026 financial guidance, including a slight increase in the lower end of its revenue and Adjusted EBITDA ranges.

Acadia Healthcare reported Q2 2026 revenue of $865.8 million, a slight decrease from the prior year. Net income attributable to the company significantly declined to $10.9 million, resulting in basic EPS of $0.12, down from $0.33 in Q2 2025. This quarter's results were impacted by an unfavorable actuarial adjustment of $28.6 million related to professional and general liability claims. The company also provided updates on ongoing legal proceedings and new accounting standards.

Acadia Healthcare Company, Inc. announced that its indirect subsidiary, San Diego Health Alliance, Inc. d/b/a Fashion Valley CTC, was found liable in an employment-related lawsuit. On May 12, 2026, a jury awarded the plaintiff $35 million in compensatory damages and $70 million in punitive damages, totaling $105 million. Both Fashion Valley and Acadia Healthcare strongly disagree with the verdict, stating it far exceeds reasonable expectations, and plan to vigorously challenge it through post-trial motions and appeals.

Acadia Healthcare Company, Inc. held its annual meeting of stockholders on May 6, 2026, where several key proposals were approved. Shareholders elected three Class III directors to serve until the 2029 annual meeting. Additionally, stockholders approved a second amendment to the company's Incentive Compensation Plan and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026. The non-binding advisory vote on executive compensation also passed.

Acadia Healthcare Company, Inc. reported a 7.6% increase in Q1 2026 revenue to $828.8 million. However, net income attributable to the company stockholders decreased by 51% to $4.1 million, resulting in basic EPS of $0.05. The quarter saw a significant rise in net cash provided by operating activities to $61.5 million and an increase in legal settlements expense, alongside receiving $31.5 million in insurance proceeds for a securities litigation settlement.

Acadia Healthcare Company, Inc. announced first quarter 2026 financial results, with revenue increasing 7.6% to $828.8 million and Adjusted EBITDA rising 7.5% to $144.2 million. However, net income attributable to Acadia decreased to $0.05 per diluted share from $0.09 in the prior-year period, and Adjusted EPS also declined. The company exceeded its Adjusted EBITDA guidance and subsequently increased its full-year 2026 Adjusted EBITDA and Adjusted EPS guidance, reflecting strong patient volumes and operating efficiencies.

Acadia Healthcare Company, Inc. announced the resignation of Todd Young as Chief Financial Officer, effective April 30, 2026. The company's Board of Directors has appointed David M. Duckworth as the Interim Chief Financial Officer, effective May 1, 2026. Mr. Duckworth, who previously served as Acadia's CFO from July 2012 to July 2023, will also assume the role of principal financial officer.